Ticker > Company >

Lasa Supergenerics share price

Lasa Supergenerics Ltd.

NSE: LASA BSE: 540702 SECTOR: Pharmaceuticals & Drugs  27k   52   4

29.46
+0.57 (1.97%)
BSE: 20 Dec 04:01 PM

Price Summary

Today's High

₹ 29.52

Today's Low

₹ 28.5

52 Week High

₹ 40.95

52 Week Low

₹ 19

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

147.6 Cr.

Enterprise Value

168.18 Cr.

No. of Shares

5.01 Cr.

P/E

0

P/B

1.63

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  18.11

CASH

1.5 Cr.

DEBT

22.08 Cr.

Promoter Holding

53.65 %

EPS (TTM)

₹  -4.53

Sales Growth

-19.47%

ROE

-20.22 %

ROCE

-13.23%

Profit Growth

43.73 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-19.47%
3 Year-19.82%
5 Year-9.26%

Profit Growth

1 Year43.73%
3 Year-198.44%
5 Year-27.98%

ROE%

1 Year-20.22%
3 Year-17.18%
5 Year-6.69%

ROCE %

1 Year-13.23%
3 Year-13.53%
5 Year-3.33%

Debt/Equity

0.2284

Price to Cash Flow

69.01

Interest Cover Ratio

-8.5966

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 53.65 20.66
Jun 2024 53.65 20.66
Mar 2024 53.65 20.66
Dec 2023 53.65 20.66
Sep 2023 53.65 20.66
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 11.2655 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 32.1483596389387.

 Limitations

  • The company has shown a poor profit growth of -198.443553738875% for the Past 3 years.
  • The company has shown a poor revenue growth of -19.8158013930484% for the Past 3 years.
  • Company has a poor ROE of -17.1842402531272% over the past 3 years.
  • Company has a poor ROCE of -13.5257916170315% over the past 3 years
  • Company has low Interest coverage ratio of -8.5966.
  • The company is trading at a high EV/EBITDA of 102.5248.
  • Promoter pledging is high as 20.66%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 24.3 26.66 22.82 30.84 39.4
Total Expenditure 23.26 25.61 26.8 29.04 38.6
Operating Profit 1.04 1.05 -3.98 1.8 0.79
Other Income 0.08 0 0.01 0.01 1.95
Interest 0.56 0.44 0.56 0.87 1.24
Depreciation 2.68 2.68 2.66 2.79 2.81
Exceptional Items 0 0 -8.77 0 0
Profit Before Tax -2.11 -2.06 -15.97 -1.86 -1.31
Tax -2.09 -0.61 -0.67 0.87 1.92
Profit After Tax -0.02 -1.46 -15.3 -2.73 -3.23
Adjusted EPS (Rs) 0 -0.29 -3.05 -0.55 -0.64

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 167.26 202.38 137.13 129.57 104.34
Total Expenditure 137.29 155.17 121.11 136.17 102.11
Operating Profit 29.97 47.21 16.02 -6.6 2.22
Other Income 0.23 0.18 0.28 1.84 0.1
Interest 8.12 2.06 0.06 4.19 1.99
Depreciation 17.34 15.82 14.51 13.42 10.67
Exceptional Items 0 0 -7.86 -19.9 -8.77
Profit Before Tax 4.74 29.49 -6.14 -42.27 -19.11
Tax 1.11 6.71 -0.81 -3.64 2.62
Net Profit 3.63 22.78 -5.33 -38.62 -21.73
Adjusted EPS (Rs.) 0.89 5.6 -1.06 -7.71 -4.34

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 40.67 40.67 50.1 50.1 50.1
Total Reserves 100.79 118.24 107.78 68.18 46.58
Borrowings 14.14 0 0 0 0
Other N/C liabilities -2.71 8.41 6.54 2.84 5.32
Current liabilities 75.92 40.54 44.75 42.73 48.87
Total Liabilities 228.81 207.86 209.17 163.85 150.87
Assets
Net Block 152.19 142.95 137.28 118.96 109.76
Capital WIP 0 0 4.58 4.64 2.51
Intangible WIP 0 0 0 0 0
Investments 0 0 0.38 0.39 0
Loans & Advances 0.75 0.59 0.63 0.59 0.71
Other N/C Assets 0 0 0 0.05 0
Current Assets 75.87 64.32 66.3 39.22 37.89
Total Assets 228.81 207.86 209.17 163.85 150.87
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 4.74 29.49 1.72 -22.37 -19.11
Adjustment 25.27 17.75 6.5 -4.07 8.42
Changes in Assets & Liabilities -16.01 -5.93 3.59 9.18 12.83
Tax Paid -0.37 0 -2.59 -0.04 0
Operating Cash Flow 13.62 41.31 9.21 -17.3 2.14
Investing Cash Flow -1.63 -3.6 -2.91 11.19 -0.4
Financing Cash Flow -9.85 -36.44 -0.04 -4.16 -1.93
Net Cash Flow 2.15 1.27 6.26 -10.27 -0.19

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 53.65 53.65 53.65 53.65 53.65
omkar pravin herleker - 53.65 - 53.65 53.65
omkar pravin herlekar 53.65 - 53.65 - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 46.35 46.35 46.35 46.35 46.35
bnp enterprises - 8.48 8.48 8.48 8.48
anil vishanji dedhia 1.80 - 1.30 - -
bebi dharma padhir 8.48 - - - -

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Company News

Lasa Supergenerics informs about closure of trading window 30 Sep, 4:58 PM Lasa Supergenerics informs about disclosure 13 Sep, 5:24 PM Lasa Supergenerics gets patent from Controller of Patents 13 Sep, 4:52 PM Lasa Supergenerics - Quaterly Results 14 Aug, 4:56 PM Lasa Supergenerics - Quaterly Results 13 Feb, 6:26 PM Lasa Supergenerics - Quaterly Results 9 Jun, 4:46 PM Lasa Supergenerics - Quaterly Results 9 Jun, 4:46 PM Lasa Supergenerics - Quaterly Results 9 Jun, 4:46 PM Lasa Supergenerics informs about postponement of board meeting 7 Jun, 4:58 PM Lasa Supergenerics informs about disclosure of related party transactions 28 Nov, 4:43 PM Lasa Supergenerics informs about outcome of board meeting 26 Aug, 4:45 PM Lasa Supergenerics - Quaterly Results 8 Aug, 3:13 PM Lasa Supergenerics - Quaterly Results 8 Aug, 3:13 PM Lasa Supergenerics secures new order of Rs 50 crore from just 5 customers 27 Apr, 10:30 AM Lasa Supergenerics reports over 3-fold jump in Q4 net profit 12 Apr, 12:07 PM Lasa Supergenerics informs about press release 11 Apr, 4:55 PM Lasa Supergenerics - Quaterly Results 11 Apr, 1:17 PM Lasa Supergenerics - Quaterly Results 11 Apr, 1:17 PM Lasa Supergenerics - Quaterly Results 11 Apr, 1:17 PM Lasa Supergenerics informs about board meeting 21 Mar, 9:45 AM Lasa Supergenerics files another suit for permanent injunction against one of its competitors 10 Mar, 9:59 AM Lasa Supergenerics - Quaterly Results 7 Feb, 3:41 PM Lasa Supergenerics - Quaterly Results 7 Feb, 3:41 PM Lasa Supergenerics - Quaterly Results 7 Feb, 3:41 PM Lasa Supergenerics informs about disclosure 4 Feb, 10:02 AM Lasa Supergenerics informs about press release 16 Dec, 9:30 AM Lasa Supergenerics resumes operations in all units situated in Mahad, Chiplun 23 Aug, 2:34 PM Lasa Supergenerics reports 85% fall in Q1 net profit 18 Aug, 12:12 PM Lasa Supergenerics board approves financial results 16 Aug, 1:42 PM Lasa Supergenerics informs about board meeting 6 Aug, 2:49 PM Lasa Supergenerics informs about press release 26 Jul, 4:24 PM Lasa Supergenerics informs about press release 9 Jun, 2:47 PM Lasa Supergenerics launches new product Oxyclozanide 9 Jun, 12:15 PM Lasa Supergenerics informs about earnings call 1 Jun, 4:35 PM Lasa Supergenerics informs about outcome of board meeting 31 May, 4:18 PM Lasa Supergenerics informs about PCS certificate 26 Apr, 3:58 PM Lasa Supergenerics submits RTA certificate 18 Jan, 1:52 PM Lasa Supergenerics gets WHO Certificate of Good Manufacturing Practices for Khed unit 12 Jan, 12:40 PM Lasa Supergenerics gets environmental clearance for Benzimidazole Derivatives Capacity Expansion 4 Nov, 12:42 PM Lasa Supergenerics informs about media release 8 Jun, 10:37 AM Lasa Supergenerics gets FDA’s nod to manufacture Progesterone0 13 Apr, 9:21 AM

Lasa Supergenerics Stock Price Analysis and Quick Research Report. Is Lasa Supergenerics an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Lasa Supergenerics and its performance over the period of time. Lasa Supergenerics stock price today is Rs 28.81.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Lasa Supergenerics cash from the operating activity was Rs 2.1388 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Lasa Supergenerics has a Debt to Equity ratio of 0.2284 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Lasa Supergenerics , the EPS growth was 43.7335 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Lasa Supergenerics has OPM of 2.13025351032731 % which is a bad sign for profitability.
     
  • ROE: Lasa Supergenerics have a poor ROE of -20.2181 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Lasa Supergenerics is Rs 28.81. One can use valuation calculators of ticker to know if Lasa Supergenerics share price is undervalued or overvalued.
Last Updated on:
Brief about Lasa Supergenerics
X